JADENU's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6596750 | NOVARTIS PHARMS CORP | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun, 2017
(6 years ago) | |
| US6465504 | NOVARTIS PHARMS CORP | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
| US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(10 years from now) | |
Jadenu is owned by Novartis Pharms Corp.
Jadenu contains Deferasirox.
Jadenu has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Jadenu are:
- US6596750
- US6465504
Jadenu was authorised for market use on 30 March, 2015.
Jadenu is available in tablet;oral dosage forms.
Jadenu can be used as method of treating chronic iron overload.
The generics of Jadenu are possible to be released after 21 November, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-241) | Jul 24, 2022 |
| Orphan Drug Exclusivity(ODE) | Jan 23, 2020 |
| M(M-239) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: Method of treating chronic iron overload
Dosage: TABLET;ORAL
How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage
JADENU family patents
